- Digital Health Cooperative Research Centre research on how an AI-driven diagnostic assistance system impacts clinical decision-making.
- Researchers found the ability of AI in clinical decision making is largelu unmeasured.
- Another DHCRC initiative being led by Sydney LHD aims to assess and enhance clinical decision-making in Australian regional and metropolitan hospital settings.
Innovative research from the Digital Health Cooperative Research Centre will explore how an AI-driven diagnostic assistance system impacts clinical decision-making and patient management at the point of care.
The initiative, which is led by Macquarie University, Sydney Local Health District, and MedTech startup annalise.ai, will focus on how the Annalise Enterprise CXR solution may assist doctors in providing secure and reliable interpretations of chest x-rays in emergency rooms. In comparison to the present practice, it will evaluate its effects on diagnostic precision, patient care, and cognitive burden.
Up to 124 results can be localized on chest x-ray images using the Annalise chest x-ray interpretation tool.
WHY IT MATTERS
While it is well known that AI may help doctors make clinical decisions, the benefits this has for the standard of care and patient safety “remain largely unmeasured,” according to DHCRC.
The use of AI can give doctors a “more timely clue on what to look” for until they can receive a full report given the limited window of time for radiologists to review and render a formal report on chest x-rays, especially during periods of high demand, explained Professor Farah Magrabi of the Australian Institute of Health Innovation at Macquarie University.
Michael Dinh, founder and director of Royal Prince Alfred Hospital’s Green Light Institute for Emergency Care, claimed that “the ability for clinical staff to have immediate access to more detailed findings will ultimately lead to better outcomes for our patients”.
“Chest x-ray remains a core medical imaging diagnostic tool, and in emergency medicine, the need for accurate, time-critical clinical decisions is paramount,” added Dr. Mark Phillips, annalise.ai’s head of Clinical Research and Medical Affairs.
THE LARGER TREND
Another DHCRC initiative being led by Sydney LHD aims to assess and enhance clinical decision-making in Australian regional and metropolitan hospital settings. The study team has identified priority areas where decision assistance tools would benefit Australian hospitals using Alcidion’s Miya Precision platform.
In related news, annalise.ai recently made important hires as it aimed to grow in the United States. Lakshmi Gudapakkam and Dr. Rick Abramson were named CEO and CMO, respectively. Their appointments followed the company’s receipt of the 510(k) clearance from the US Food and Drug Administration for Annalise Enterprise CXR in March.
Global Artificial Intelligence Summit & Awards
If you or your organization is building cutting-edge AI solutions to adapt to a world driven by technology, Please nominate yourself/or your company for GAISA AWARDS 2022.
Please follow the below-given link to nominate:https://gaisa.in/award
All further details regarding the event will be updated on the official website of Gaisa 2022. Please Visit: https://gaisa.in/